Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
2010

Immune Response in Ovarian Cancer

publication Evidence: moderate

Author Information

Author(s): Nikos G. Gavalas, Alexandra Karadimou, Meletios A. Dimopoulos, Aristotelis Bamias

Primary Institution: Department of Clinical Therapeutics, Medical School, University of Athens

Hypothesis

How is the immune system involved in the prognosis and therapy of ovarian cancer?

Conclusion

The immune response plays a significant role in the prognosis and treatment of ovarian cancer, with various immune cell populations influencing disease outcomes.

Supporting Evidence

  • Ovarian cancer is often diagnosed at advanced stages, leading to poor prognosis.
  • Immune cell populations, such as T cells, are associated with disease outcomes.
  • Resistance to chemotherapy is common in ovarian cancer, necessitating new treatment strategies.
  • VEGF plays a critical role in tumor progression and immune evasion in ovarian cancer.
  • Regulatory T cells (Tregs) are linked to poor prognosis in ovarian cancer patients.

Takeaway

Ovarian cancer can be tough to treat, but understanding how the immune system fights it can help doctors find better ways to help patients.

Methodology

The paper reviews recent developments in understanding the immune response mechanisms in ovarian cancer and their prognostic significance.

Limitations

The study highlights the complexity of the immune response and the need for further research to clarify mechanisms and improve treatment strategies.

Digital Object Identifier (DOI)

10.1155/2010/791603

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication